SparingVision

Executive Summary

SparingVision is a Paris-based genomic medicines company pioneering a step-change in the treatment of inherited retinal diseases (IRDs). Unlike traditional gene therapies that target single genetic defects, SparingVision's platform aims to address IRDs irrespective of genetic cause, offering broad applicability to a patient population with high unmet need. The company leverages novel RNA and gene therapy approaches to develop treatments that can halt or reverse vision loss. Currently in Phase 1 development, SparingVision is poised to generate initial clinical data that could validate its platform and differentiate it from competitors focused on monogenic correction. The company's vision to treat all IRD patients, regardless of mutation, positions it as a potential leader in ocular genomic medicine, with significant commercial and therapeutic upside if clinical proof-of-concept is achieved.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead candidate60% success
• Q4 2026Strategic partnership or licensing deal for platform technology50% success
• Q2 2026FDA acceptance of IND for second program70% success